Healthcare stocks have gotten crushed in 2024, and next year doesn’t look much better. But there are still opportunities for ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Novo Nordisk and Eli Lilly face soaring demand--and stiff competition--as obesity drug market transforms healthcare and ...

CEO's newfound preference for Eli Lilly's (NYSE:LLY) weight loss therapy Mounjaro over Novo Nordisk's (NVO) rival product ...

In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...

Discover how Mounjaro the revolutionary weight-loss and diabetes drug by Eli Lilly is set to transform obesity management in ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight loss drugs.

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...